Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells

British Journal of Cancer

Volumn 106, Issue 11, 2012, Pages 1772-1778

  Wang, J ^a,b   Hughes, T P ^a,b   Kok, C H ^a,b   Saunders, V A ^a   Frede, A ^a   Groot Obbink, K ^a   Osborn, M ^a,c   Somogyi, A A ^b   D'Andrea, R J ^a,b,d   White, D L ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

CML; drug drug interaction; imatinib; NSAIDs; OCT 1

Indexed keywords

DICLOFENAC; IBUPROFEN; IMATINIB; MESSENGER RNA; ORGANIC CATION TRANSPORTER 1;

ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DICLOFENAC; DRUG INTERACTIONS; HUMANS; IBUPROFEN; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; ORGANIC CATION TRANSPORTER 1; PIPERAZINES; PYRIMIDINES;

EID: 84861454785     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.173     Document Type: Article

References (42)

1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H (1999) Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol 55(5): 847-854 (Pubitemid 29214604)
2. Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P (2008) Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: Role of COX-2 and MDR-1. Leuk Res 32(6): 855-864
3. Bachmakov I, Glaeser H, Fromm MF, Konig J (2008) Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 57(6): 1463-1469
4. Bjorkman D (1998) Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 105(5 A): 17S-21S
5. Bramlage P, Goldis A (2008) Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. BMC Pharmacol 8: 1471-1487
6. Ciarimboli G, Koepsell H, Iordanova M, Gorboulev V, Dürner B, Lang D, Edemir B, Schröter R, Van Le T, Schlatter E (2005) Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 16(6): 1562-1570 (Pubitemid 41716463)
7. Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, Schlatter E, Hirsch JR (2004) Regulation of the human organic cation transporter hOCT1. J Cell Physiol 201(3): 420-428 (Pubitemid 39456441)
8. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28(3): 424-430
9. Deininger MWN, O'Brien SG, Ford JM, Druker BJ (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21(8): 1637-1647 (Pubitemid 46594119)
10. Fahrmayr C, Fromm MF, König J (2010) Hepatic OATP and OCT uptake transporters: Their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 42(3): 380-401
11. Farooq M, Haq I, Qureshi AS (2008) Cardiovascular risks of COX inhibition: Current perspectives. Expert Opin Pharmacother 9(8): 1311-1319 (Pubitemid 351877515)
12. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE (2008) Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112(8): 3348-3354
13. Giles FJ, Kantarjian HM, Bekele BN, Cortes JE, Faderl S, Thomas DA, Manshouri T, Rogers A, Keating MJ, Talpaz M, O'Brien S, Albitar M (2002) Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 119(1): 38-45 (Pubitemid 35176496)
14. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Nagesh Rao P, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531): 876-880 (Pubitemid 32743979)
15. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14(12): 3881-3888
16. Holle SK, Ciarimboli G, Edemir B, Neugebauer U, Pavenstädt H, Schlatter E (2011) Properties and regulation of organic cation transport in freshly isolated mouse proximal tubules analyzed with a fluorescence reader-based method. Pflugers Archiv Eur J Physiol 462(2): 359-369
17. Honjo H, Uwai Y, Aoki Y, Iwamoto K (2011) Stereoselective inhibitory effect of flurbiprofen, ibuprofen and naproxen on human organic anion transporters hOAT1 and hOAT3. Biopharm Drug Dispos 32(9): 518-524
18. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NCP, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1): 28-37 (Pubitemid 43990609)
19. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz H, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy. Blood 112(10): 3965-3973
20. Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19): 3758-3765
21. Juhlin T, Björkman S, Gunnarsson B, Fyge A, Roth B, Höglund P (2004) Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail 6(7): 909-916 (Pubitemid 39536307)
22. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D (2008) Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 36(8): 1616-1623
23. Kalle AM, Sachchidanand S, Pallu R (2010) Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk Res 34(9): 1132-1138
24. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, Endou H (2002) Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303(2): 534-539 (Pubitemid 35231223)
25. Kindla J, Fromm MF, Konig J (2009) In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 5(5): 489-500
26. Minematsu T, Giacomini KM (2011) Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters, OCTs, and Multidrug and Toxic Compound Extrusion Proteins, MATEs. Mol Cancer Ther 10(3): 531-539
27. Mulato AS, Ho ES, Cihlar T (2000) Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 295(1): 10-15
28. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y (2004) Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 309(1): 226-234 (Pubitemid 38393134)
29. Perneger TV, Whelton PK, Klag MJ (1994) Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331(25): 1675-1679 (Pubitemid 24373619)
30. Rich SA (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345(23): 1709
31. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2): 117-125 (Pubitemid 41039112)
32. Siu SSN, Yeung JHK, Lau TK (2000) A study on placental transfer of diclofenac in first trimester of human pregnancy. Hum Reprod 15(11): 2423-2425
33. Subhashini J, Mahipal SVK, Reddanna P (2005) Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224(1): 31-43 (Pubitemid 40720365)
34. Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104(12): 3739-3745 (Pubitemid 39564452)
35. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer 6(2): 130-140 (Pubitemid 43361545)
36. Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H (2008) Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica 38(9): 1203-1218
37. White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T (2007a) Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 25(28): 4445-4451 (Pubitemid 350013851)
38. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T (2005) In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106(7): 2520-2526 (Pubitemid 41510828)
39. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP (2010) Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28(16): 2761-2767
40. White DL, Hughes TP (2012) Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response. J Clin Oncol 30(10): 1144-1145
41. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T (2007b) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110(12): 4064-4072 (Pubitemid 350248463)
42. White DL, Saunders VA, Dang P, Engler J, Zannettino ACW, Cambareri AC, Quinn SR, Manley PW, Hughes TP (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108(2): 697-704 (Pubitemid 44061372)